Analysts Set MindWalk Holdings Corp. (NASDAQ:HYFT) Target Price at $5.00

MindWalk Holdings Corp. (NASDAQ:HYFT) has earned an average recommendation of “Hold” from the five analysts that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $5.00.

A number of equities analysts have weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of MindWalk in a report on Wednesday, July 15th. Zacks Research lowered shares of MindWalk from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 28th. Wall Street Zen upgraded MindWalk from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of MindWalk in a research report on Monday, July 20th.

MindWalk Stock Up 3.8%

Shares of MindWalk stock opened at $1.36 on Friday. MindWalk has a one year low of $0.99 and a one year high of $2.99. The company has a market cap of $63.53 million, a P/E ratio of -5.23 and a beta of 0.82. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.72 and a current ratio of 1.84. The firm has a fifty day moving average of $1.36 and a two-hundred day moving average of $1.36.

MindWalk (NASDAQ:HYFT) last announced its earnings results on Monday, September 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04). MindWalk had a negative return on equity of 133.26% and a negative net margin of 105.11%.The business had revenue of $2.75 million for the quarter, compared to analyst estimates of $3.25 million. On average, analysts forecast that MindWalk will post -0.21 earnings per share for the current year.

Institutional Trading of MindWalk

A hedge fund recently bought a new position in MindWalk stock. GSA Capital Partners LLP purchased a new stake in shares of MindWalk Holdings Corp. (NASDAQ:HYFT) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 34,525 shares of the company’s stock, valued at approximately $55,000. GSA Capital Partners LLP owned 0.07% of MindWalk as of its most recent filing with the Securities and Exchange Commission (SEC). 6.70% of the stock is currently owned by institutional investors and hedge funds.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.